CHARLES SCHWAB INVESTMENT MANAGEMENT INC - CRINETICS PHARMACEUTICALS IN ownership

CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 50 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2018. The put-call ratio across all filers is - and the average weighting 0.4%.

Quarter-by-quarter ownership
CHARLES SCHWAB INVESTMENT MANAGEMENT INC ownership history of CRINETICS PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$13,719,151
+117.1%
461,303
+31.5%
0.00%
+100.0%
Q2 2023$6,320,299
+13.9%
350,738
+1.5%
0.00%0.0%
Q1 2023$5,549,806
-11.6%
345,567
+0.7%
0.00%0.0%
Q4 2022$6,277,907
-4.9%
343,055
+2.0%
0.00%0.0%
Q3 2022$6,603,000
+6.7%
336,190
+1.4%
0.00%0.0%
Q2 2022$6,186,000
-5.5%
331,671
+11.3%
0.00%0.0%
Q1 2022$6,544,000
-20.5%
298,125
+2.9%
0.00%0.0%
Q4 2021$8,232,000
+75.1%
289,735
+29.8%
0.00%0.0%
Q3 2021$4,700,000
+27.2%
223,247
+13.9%
0.00%
+100.0%
Q2 2021$3,694,000
+60.3%
195,921
+30.0%
0.00%0.0%
Q1 2021$2,304,000
+8.3%
150,752
+0.0%
0.00%0.0%
Q4 2020$2,127,000
-7.6%
150,723
+2.6%
0.00%0.0%
Q3 2020$2,302,000
-2.7%
146,871
+8.8%
0.00%0.0%
Q2 2020$2,365,000
+204.8%
134,974
+156.0%
0.00%
Q1 2020$776,000
-41.6%
52,722
-0.4%
0.00%
-100.0%
Q4 2019$1,329,000
+73.0%
52,947
+3.8%
0.00%
Q3 2019$768,000
-33.4%
51,003
+10.5%
0.00%
-100.0%
Q2 2019$1,154,000
+26.0%
46,146
+14.7%
0.00%0.0%
Q1 2019$916,000
-9.8%
40,217
+18.7%
0.00%0.0%
Q4 2018$1,016,000
-1.7%
33,874
-6.1%
0.00%0.0%
Q3 2018$1,034,00036,0660.00%
Other shareholders
CRINETICS PHARMACEUTICALS IN shareholders Q3 2018
NameSharesValueWeighting ↓
Versant Venture Management, LLC 2,030,616$31,028,0006.04%
5AM Venture Management, LLC 1,362,286$20,816,0003.75%
Burrage Capital Management LLC 272,393$4,162,0003.37%
Altium Capital Management LP 361,930$5,530,0001.54%
Vivo Capital, LLC 2,214,138$33,832,0001.19%
Bain Capital Life Sciences Investors, LLC 1,071,428$16,371,0000.93%
Perceptive Advisors 3,659,381$51,606,0000.65%
New Leaf Venture Partners, L.L.C. 141,000$2,154,0000.50%
DRIEHAUS CAPITAL MANAGEMENT LLC 2,003,688$30,616,0000.45%
Opaleye Management Inc. 188,000$2,873,0000.42%
View complete list of CRINETICS PHARMACEUTICALS IN shareholders